Immutep Q4 FY26 Cash A$68.87M; TACTI-004 Futility Analysis Ongoing
Immutep Ltd reported its Q4 FY26 activities, ending the quarter with A$68.87 million in cash, cash equivalents, and term deposits, extending its cash runway into H1 CY28. The company provided updates on its clinical programs, including positive pooled analysis data for eftilagimod alfa (efti) showing a 7.7-month median overall survival benefit and encouraging Phase I results for IMP761. However, the investigation into the futility outcome of the TACTI-004 Phase III trial is ongoing, and Novartis terminated its out-license agreement for ieramilimab. The company also initiated cost-reduction measures and reported net cash used in operating activities of A$38.891 million, which included a A$14.092 million repayment to Dr. Reddy's.
Key Highlights
- Ended Q4 FY26 with A$68.87 million in cash, cash equivalents, and term deposits.
- Extended cash runway into H1 CY28 through initiated cost-reduction measures.
- Pooled analysis of five efti trials showed 7.7-month median overall survival benefit in biological responders.
- IMP761 Phase I trial met primary safety endpoint and showed significant pharmacodynamic activity.
- Investigation into TACTI-004 futility outcome continues, with an update expected in Q3 CY26.
- Novartis terminated the out-license agreement for ieramilimab (LAG525) effective August 9, 2026.
- Net cash used in operating activities was A$38.891 million for the quarter.
- Repaid US$10 million (A$14.092 million) to Dr. Reddy's following TACTI-004 discontinuation.
Price Impact
More from IMMP